Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||P30-EPS + Poly ICLC|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|P30-EPS||P30EPS|P30 EPS||P30-EPS is a peptide vaccine that consist of EphA2, survivin and cytomegalovirus matrix protein pp65 linked to tetanus toxoid epitope P30, which may lead to a cytotoxic T-lymphocyte mediated response against EphA2, CMV pp65 and survivin-expressing tumor cells (NCI Drug Dictionary).|
|Poly ICLC||Hiltonol||Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05283109||Phase I||P30-EPS + Poly ICLC||ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I)||Not yet recruiting||USA||0|